MOLN Intrinsic Valuation and Fundamental Analysis - Molecular Partners AG - Alpha Spread

Molecular Partners AG
NASDAQ:MOLN

Watchlist Manager
Molecular Partners AG Logo
Molecular Partners AG
NASDAQ:MOLN
Watchlist
Price: 4.67 USD -3.51% Market Closed
Market Cap: 155m USD
Have any thoughts about
Molecular Partners AG?
Write Note

Intrinsic Value

MOLN's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one MOLN stock under the Base Case scenario is 3.37 USD. Compared to the current market price of 4.67 USD, Molecular Partners AG is Overvalued by 28%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

MOLN Intrinsic Value
3.37 USD
Overvaluation 28%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Molecular Partners AG

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling MOLN based on its intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?
How do you feel about MOLN?
Bearish
Neutral
Bullish

Fundamental Analysis

Summary

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Wall St Estimates
Price Target
Loading
Revenue Forecast
Operating Income Forecast
Earnings Forecast
No Indicators Selected
Select Indicators
Investor Returns
Shareholder Yield
Dividend Safety
Dividend Yield
Dividend Payout Ratio
Buyback Yield
Debt Paydown Yield
No Indicators Selected
Select Indicators
Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

AI Assistant
AI Assistant
Ask me anything about Molecular Partners AG

Provide an overview of the primary business activities
of Molecular Partners AG.

What unique competitive advantages
does Molecular Partners AG hold over its rivals?

What risks and challenges
does Molecular Partners AG face in the near future?

Summarize the latest earnings call
of Molecular Partners AG.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Molecular Partners AG.

Provide P/S
for Molecular Partners AG.

Provide P/E
for Molecular Partners AG.

Provide P/OCF
for Molecular Partners AG.

Provide P/FCFE
for Molecular Partners AG.

Provide P/B
for Molecular Partners AG.

Provide EV/S
for Molecular Partners AG.

Provide EV/GP
for Molecular Partners AG.

Provide EV/EBITDA
for Molecular Partners AG.

Provide EV/EBIT
for Molecular Partners AG.

Provide EV/OCF
for Molecular Partners AG.

Provide EV/FCFF
for Molecular Partners AG.

Provide EV/IC
for Molecular Partners AG.

Show me price targets
for Molecular Partners AG made by professional analysts.

What are the Revenue projections
for Molecular Partners AG?

How accurate were the past Revenue estimates
for Molecular Partners AG?

What are the Net Income projections
for Molecular Partners AG?

How accurate were the past Net Income estimates
for Molecular Partners AG?

What are the EPS projections
for Molecular Partners AG?

How accurate were the past EPS estimates
for Molecular Partners AG?

What are the EBIT projections
for Molecular Partners AG?

How accurate were the past EBIT estimates
for Molecular Partners AG?

Compare the revenue forecasts
for Molecular Partners AG with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Molecular Partners AG and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Molecular Partners AG against its competitors.

Analyze the profit margins
(gross, operating, and net) of Molecular Partners AG compared to its peers.

Compare the P/E ratios
of Molecular Partners AG against its peers.

Discuss the investment returns and shareholder value creation
comparing Molecular Partners AG with its peers.

Analyze the financial leverage
of Molecular Partners AG compared to its main competitors.

Show all profitability ratios
for Molecular Partners AG.

Provide ROE
for Molecular Partners AG.

Provide ROA
for Molecular Partners AG.

Provide ROIC
for Molecular Partners AG.

Provide ROCE
for Molecular Partners AG.

Provide Gross Margin
for Molecular Partners AG.

Provide Operating Margin
for Molecular Partners AG.

Provide Net Margin
for Molecular Partners AG.

Provide FCF Margin
for Molecular Partners AG.

Show all solvency ratios
for Molecular Partners AG.

Provide D/E Ratio
for Molecular Partners AG.

Provide D/A Ratio
for Molecular Partners AG.

Provide Interest Coverage Ratio
for Molecular Partners AG.

Provide Altman Z-Score Ratio
for Molecular Partners AG.

Provide Quick Ratio
for Molecular Partners AG.

Provide Current Ratio
for Molecular Partners AG.

Provide Cash Ratio
for Molecular Partners AG.

What is the historical Revenue growth
over the last 5 years for Molecular Partners AG?

What is the historical Net Income growth
over the last 5 years for Molecular Partners AG?

What is the current Free Cash Flow
of Molecular Partners AG?

Discuss the annual earnings per share (EPS)
trend over the past five years for Molecular Partners AG.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Molecular Partners AG

Current Assets 165.6m
Cash & Short-Term Investments 159.1m
Receivables 3.4m
Other Current Assets 3.1m
Non-Current Assets 5m
PP&E 4.9m
Intangibles 122k
Current Liabilities 11.4m
Accounts Payable 2.9m
Accrued Liabilities 6.7m
Other Current Liabilities 1.8m
Non-Current Liabilities 3.7m
Long-Term Debt 1.8m
Other Non-Current Liabilities 1.9m
Efficiency

Earnings Waterfall
Molecular Partners AG

Revenue
10.4m CHF
Operating Expenses
-85.9m CHF
Operating Income
-75.5m CHF
Other Expenses
6.4m CHF
Net Income
-69.1m CHF

Free Cash Flow Analysis
Molecular Partners AG

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

MOLN Profitability Score
Profitability Due Diligence

Molecular Partners AG's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
ROE is Increasing
Positive 3-Years Revenue Growth
Negative 1-Year Revenue Growth
30/100
Profitability
Score

Molecular Partners AG's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

MOLN Solvency Score
Solvency Due Diligence

Molecular Partners AG's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
75/100
Solvency
Score

Molecular Partners AG's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MOLN Price Targets Summary
Molecular Partners AG

Wall Street analysts forecast MOLN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MOLN is 8.76 USD with a low forecast of 3.6 USD and a high forecast of 18.69 USD.

Lowest
Price Target
3.6 USD
23% Downside
Average
Price Target
8.76 USD
87% Upside
Highest
Price Target
18.69 USD
300% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for MOLN?

Click here to dive deeper.

Shareholder Yield

Current shareholder yield for MOLN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Want to learn more about MOLN dividends, buybacks, and debt paydown yield?

Click here to dive deeper.

MOLN Price
Molecular Partners AG

1M 1M
-28%
6M 6M
+21%
1Y 1Y
+8%
3Y 3Y
-76%
5Y 5Y
-72%
10Y 10Y
-80%
Annual Price Range
4.67
52w Low
3.32
52w High
11.01
Price Metrics
Average Annual Return -12.34%
Standard Deviation of Annual Returns 38.39%
Max Drawdown -90%
Shares Statistics
Market Capitalization 155m USD
Shares Outstanding 33 182 600
Percentage of Shares Shorted 0.11%

Competitive Landscape

MOLN News

Other Videos

Profile

Molecular Partners AG Logo
Molecular Partners AG

Country

Switzerland

Industry

Biotechnology

Market Cap

155m USD

Dividend Yield

0%

Description

Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. The company is headquartered in Schlieren, Zuerich and currently employs 163 full-time employees. The company went IPO on 2014-10-22. The firm has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.

Contact

ZUERICH
Schlieren
Wagistrasse 14
+41447557700.0
www.molecularpartners.com

IPO

2014-10-22

Employees

163

Officers

See Also

Discover More
What is the Intrinsic Value of one MOLN stock?

The intrinsic value of one MOLN stock under the Base Case scenario is 3.37 USD.

Is MOLN stock undervalued or overvalued?

Compared to the current market price of 4.67 USD, Molecular Partners AG is Overvalued by 28%.

Back to Top